Andrew Pickering

Andrew Pickering

Auto-generated profile, based on publicly available information

Andrew Pickering

Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2019 in Journal of Controlled Release
Verified
Journal Article
Closed access
MHMarian H. Hettiaratchi
Marian H. Hettiaratchi
MOMatthew J. O'MEara
Matthew J. O'MEara
CTCarter J. Teal
Carter J. Teal
SPSamantha L. Payne
Samantha L. Payne
APAndrew J. Pickering
Andrew J. Pickering
Molly ShoichetMolly Shoichet
Molly Shoichet

21 August 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
MHMarian H. Hettiaratchi
Marian H. Hettiaratchi
MOMatthew J. O’mEara
Matthew J. O’mEara
TOTeresa O'Meara
Teresa O'Meara
APAndrew J. Pickering
Andrew J. Pickering
NLNitzan Letko-Khait
Nitzan Letko-Khait
Molly ShoichetMolly Shoichet
Molly Shoichet
Computational redesign of chondroitinase ABC introduces 37 point mutations to improve enzyme stability and activity.

22 November 2023 in ACS Nano
Verified
Journal Article
Closed access
APAndrew J. Pickering
Andrew J. Pickering
NLNicholas G. Lamson
Nicholas G. Lamson
MMMichael H. Marand
Michael H. Marand
WHWei Hwang
Wei Hwang
Joelle StraehlaJoelle Straehla
Joelle Straehla
PHPaula Hammond
Paula Hammond

10 April 2020 in Biomacromolecules
Verified
Journal Article
Closed access
VDVianney Delplace
Vianney Delplace
APAndrew J. Pickering
Andrew J. Pickering
MHMarian H. Hettiaratchi
Marian H. Hettiaratchi
SZSpencer Zhao
Spencer Zhao
TKTove Kivijärvi
Tove Kivijärvi
Molly ShoichetMolly Shoichet
Molly Shoichet

23 September 2016 in Macromolecules
Verified
Journal Article
Closed access
BFBo Fan
Bo Fan
JTJohn Trant
John Trant
RYRebecca E. Yardley
Rebecca E. Yardley
APAndrew J. Pickering
Andrew J. Pickering
FLFrançois Lagugné-Labarthet
François Lagugné-Labarthet
Elizabeth GilliesElizabeth Gillies
Elizabeth Gillies

31 October 2025 in Nature Materials
Verified
Journal Article
Open access
PDF file
IPIvan S. Pires
Ivan S. Pires
GCGil Covarrubias
Gil Covarrubias
VGVictoria F. Gomerdinger
Victoria F. Gomerdinger
CBCoralie Backlund
Coralie Backlund
EBEduardo Nombera Bueno
Eduardo Nombera Bueno
PHPaula Hammond
Paula Hammond
Immunotherapies such as immune checkpoint inhibitors are effective in treating several advanced cancers, but these treatments have had limited success in metastatic ovarian cancer. Here we engineered liposomal nanoparticles carrying a poly- ʟ -arginine/poly- ʟ -glutamate coating that promotes their binding and retention on the surface of ovarian cancer cells. Covalent anchoring of the potent immunostimulatory cytokine interleukin-12 (IL-12) to phospholipid headgroups of the liposome core enabled the polymer-coated particles to concentrate IL-12 in disseminated ovarian cancer tumours following intraperitoneal administration. Shedding of the layer-by-layer coating and serum-protein-mediated extraction of IL-12-conjugated lipids from the liposomal core over time enabled IL-12 to disseminate in the tumour bed following rapid nanoparticle localization in tumour nodules. Optimized IL-12-polymer-coated nanoparticles promoted robust T cell accumulation in ascites and tumours in mouse models, extending survival compared with free IL-12 and sensitizing tumours to immune checkpoint inhibitors, eliciting strong immune responses and immune memory. Overall, these findings support the potential of these polymer-coated nanoparticles for the sustained delivery of IL-12 to disseminated metastatic ovarian cancer.